A. Orjales et al., “New (2-methoxyphenyl) piperazine derivatives as 5-HT 1A receptor ligands with reduced alpha-1-adrenergic activity. Synthesis and structure-affinity activity. Synthesis and structure-affinity relationships.” Journal of Medicinal Chemistry., vol. 38, No 8, 1995, pp. 1273-1277, XP-002074046. |
R.K. Raghupathi et al.: “Analogues of the 5-HT-1A serotonin antagonist 1-(2-methoxyphenyl)-4-′4-(2-phthalimido)butyl!piperazine with reduced alpha-1-adrenergic affinity”Journal of Medicinal Chemistry, vol .34, No. 8, 1991, pp. 2633-2638, XP002074047. |
Breslin D, Fields DW, Chou TC, Marion DN, Kane M, Vaughan ED, and Felsen D (1993) Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. 149:395-399. |
Hatano A., Takahashi H, Tamaki M, Komeyama T, Koizumi T, and Takeda M (1994) Pharmacological evidence of a distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. 113:723-728. |
Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperlasia. J. Urol. 148:1467-1474. |